Prospective, Open-Label Comparative Study of Liver Toxicity in an Unselected Population of HIV-Infected Patients Treated for the First Time with Efavirenz or Nevirapine-Reference-Cited by-同舟云学术

Prospective, Open-Label Comparative Study of Liver Toxicity in an Unselected Population of HIV-Infected Patients Treated for the First Time with Efavirenz or Nevirapine

Published:2005-12 Issue:6 Volume:6 Page:302-311
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Manfredi Roberto,Calza Leonardo,Chiodo Francesco

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

http://www.tandfonline.com/doi/pdf/10.1310/EWWC-YLJ6-8LHE-054A

Reference39 articles.

1. Safety and Tolerance of Efavirenz in Different Antiretroviral Regimens: Results from a National Multicenter Prospective Study in 1,033 HIV-Infected Patients

2. Nevirapine in the treatment of HIV

3. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management

4. Incidence of Liver Toxicity in HIV-Infected Patients Receiving Isolated Dual Nucleoside Analogue Antitretroviral Therapy

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ncBAF enhances PXR-mediated transcriptional activation in the human and mouse liver;Biochemical Pharmacology;2023-09

2. ncBAF, a chromatin remodeler, enhances PXR-mediated transcriptional activation in the human and mouse liver;2023-02-04

3. Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs;CNS Spectrums;2018-10-08

4. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals;Cochrane Database of Systematic Reviews;2016-12-10

5. Early changes in hepatic function among HIV–tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy;International Journal of Infectious Diseases;2013-12